Stockscreener 앱 받기
240.68
1.45%
4.3444
전일 마감가:
$236.34
열려 있는:
$235.87
하루 거래량:
108.69K
Relative Volume:
0.31
시가총액:
$6.62B
수익:
$2.58B
순이익/손실:
$-778.69M
주가수익비율:
-8.8066
EPS:
-27.33
순현금흐름:
$223.75M
1주 성능:
-0.17%
1개월 성능:
+6.28%
6개월 성능:
-35.94%
1년 성능:
-14.32%
1일 변동 폭
$233.10
$243.13
1주일 범위
$233.10
$255.00
52주 변동 폭
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(510) 724-7000
주소
1000 ALFRED NOBEL DRIVE, HERCULES
BIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
240.82 | 6.62B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
132.22 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.51 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.21 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.41 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.40 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-06-16 | 개시 | Wells Fargo | Overweight |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-01-28 | 재확인 | Citigroup | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2018-10-17 | 개시 | Goldman | Buy |
| 2018-09-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-02-16 | 다운그레이드 | CL King | Buy → Neutral |
| 2017-07-13 | 개시 | Wells Fargo | Outperform |
| 2017-06-28 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Hold |
| 2016-10-13 | 개시 | CL King | Buy |
| 2015-05-06 | 재확인 | Jefferies | Buy |
| 2009-12-18 | 개시 | Maxim Group | Buy |
| 2009-11-06 | 개시 | Jefferies & Co | Buy |
| 2009-07-17 | 개시 | Soleil | Buy |
| 2007-09-26 | 개시 | Banc of America Sec | Buy |
| 2007-02-23 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
U.S. Hemoglobinopathy Market 2025-2032: Top Trends & Growth - openPR.com
One Step RT-qPCR Kits Market Top Players- Takara Bio Inc., - openPR.com
Laboratory Proficiency Testing Market Is Booming Worldwide | - openPR.com
Biodetection Market Deep Research 2025-2032 | Bio-Rad - openPR.com
Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report - Yahoo Finance
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Bio-Rad Earnings: Revenue Declines Driven by Weak Academic Research Market; Guidance Lowered - Morningstar
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Ra - GuruFocus
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Rad Laboratories | BIO Stock News - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | B - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | BIO Stock News - GuruFocus
Bio-Rad's Steady Business and Stake in Sartorius Driving Long-Term Value - Morningstar
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Cell-Based Assays: The Future of Biomedical Breakthroughs - GlobeNewswire Inc.
Bio-Rad (BIO) Target Price Cut by UBS Amid Macroeconomic Concerns | BIO Stock News - GuruFocus
Bio-Rad (BIO) Sees Price Target Reduced by Citi Analyst After Q1 Report | BIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Biosensors Market Future Business Opportunities 2025-2032 | - openPR.com
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket - Yahoo Finance
Biomarker Testing Market: Trends, Growth, and Key Insights 2025 - openPR.com
Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo
Bio Rad Laboratories Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bio-Rad Laboratories Reports Q1 2025 Financial Results - TipRanks
Bio-Rad: Q1 Earnings Snapshot - MySA
Bio-Rad Laboratories (BIO) Faces Revenue Challenges Amid Market Headwinds - GuruFocus
Bio-Rad Laboratories Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Bio-Rad Labs exceeds Q1 2025 earnings expectations - Investing.com
Bio-Rad Reports First-Quarter 2025 Financial Results - BioSpace
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook By Investing.com - Investing.com South Africa
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook - Investing.com
Bio-Rad Laboratories Expects 2025 Non-GAAP Revenue to Range From 1% Drop to 1.5% Growth Vs. Prior Est 1.5% to 3.5% Gain - marketscreener.com
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates - Yahoo Finance
Bio-Rad (BIO) Revises 2025 Financial Projections | BIO Stock New - GuruFocus
Bio-Rad Reports First-Quarter 2025 Financial Results | BIO Stock News - GuruFocus
BIO Surpasses Q1 Revenue Expectations, Adjusts 2025 Outlook | BI - GuruFocus
BIO-RAD LABORATORIES, INC. SEC 10-Q Report - TradingView
Earnings Flash (BIO) Bio-Rad Laboratories Reports Q1 Revenue $585.4M, vs. FactSet Est of $573.3M - marketscreener.com
Lyme Disease Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
A Preview Of Bio-Rad Laboratories's Earnings - Nasdaq
Molecular Quality Control Market Report: Insights, Analysis & - openPR.com
(BIO) Proactive Strategies - news.stocktradersdaily.com
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential - MSN
Malaria Diagnostics Market Overall Study Report 2025-2032 | - openPR.com
Biodesix and Bio-Rad Drive Advances in ctDNA-Based Cancer Therapies - Technology Networks
Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile? - MSN
Biopharmaceutical Processing Equipment and Consumables - openPR.com
Laboratory Proficiency Testing Market Projected To Witness - openPR.com
Bio Rad Laboratories Inc (BIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.11%
0.04%
자본화:
|
볼륨(24시간):